Genetic alteration of class I HLA in cutaneous T-cell lymphoma.

Autor:	Kwang AC; Stanford University School of Medicine, Palo Alto, California, United States., Duran GE; Stanford University School of Medicine, Palo Alto, California, United States., Fernandez-Pol S; Stanford University, Stanford, California, United States., Najidh S; Stanford University School of Medicine, Palo Alto, California, United States., Li S; Stanford University School of Medicine., Bastidas Torres AN; Stanford University School of Medicine, Palo Alto, California, United States., Wang EB; Stanford University School of Medicine, Stanford, California, United States., Herrera M; Stanford University School of Medicine, Stanford, California, United States., Bandali TI; Stanford University School of Medicine, Stanford, California, United States., Kurtz DM; Stanford University, Palo Alto, California, United States., Kim YH; Stanford University School of Medicine, Palo Alto, California, United States., Khodadoust MS; Stanford University, Stanford, California, United States.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2024 Oct 10. Date of Electronic Publication: 2024 Oct 10.
DOI:	10.1182/blood.2024024817
Abstrakt:	Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCL). We characterized the occurrence of class I HLA abnormalities in 65 patients with advanced mycosis fungoides (MF) or Sézary syndrome (SS). Targeted DNA sequencing including coverage of HLA loci revealed at least one HLA abnormality in 26/65 patients (40%). Twelve unique somatic HLA mutations were identified across nine patients, and loss of heterozygosity or biallelic loss of HLA was found to affect 24 patients. Although specific HLA alleles were commonly disrupted, these events did not associate with decreased total class I HLA expression. Genetic events preferentially disrupted HLA alleles capable of presentation of greater numbers of putative neoantigens. HLA abnormalities co-occurred with other genetic immune evasion events and were associated with worse progression-free survival. Single-cell analyses demonstrated HLA abnormalities were frequently subclonal. Through analysis of serial samples, we observed disrupting class I HLA events change dynamically over the disease course. The dynamics of HLA disruption are highlighted in a patient receiving pembrolizumab, where resistance to pembrolizumab was associated with elimination of an HLA mutation. Overall, our findings show that genomic class I HLA abnormalities are common in advanced CTCL and may be an important consideration in understanding the effects of immunotherapy in CTCL. (Copyright © 2024 American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu